Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 10:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 477 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chimera Clear all
Completed Phase 1 Interventional

Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients

NCT00085930
View directory record Official record
Conditions
Neuroblastoma
Interventions
EBV specific CTLs
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 21 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 29, 2026, 10:13 PM EDT
Active, not recruiting Phase 1 Interventional

Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma

NCT05539430
View directory record Official record
Conditions
Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer, Pancreatic Cancer
Interventions
LB1908
Biological
Lead sponsor
Legend Biotech USA Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
9
States / cities
Tampa, Florida • Detroit, Michigan • Hackensack, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 29, 2026, 10:13 PM EDT
Recruiting No phase listed Observational

Long-term Follow-up (LTFU) of Participants Who Received Azer-Cel

NCT07577583
View directory record Official record
Conditions
B-cell Mediated Autoimmune Disorders
Interventions
No Intervention
Other
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years to 62 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2039
U.S. locations
1
States / cities
Morrisville, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 29, 2026, 10:13 PM EDT
Active, not recruiting Phase 1 Interventional

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

NCT03233854
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, CD19 Positive, Minimal Residual Disease, Philadelphia Chromosome Positive
Interventions
Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Questionnaire Administration, NKTR-255
Biological · Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2035
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 29, 2026, 10:13 PM EDT
Completed Phase 1 Interventional

A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer

NCT00325494
View directory record Official record
Conditions
Pancreatic Cancer, Mesothelioma, Ovarian Cancer, Non-Small Cell Lung Cancer
Interventions
MORAb-009
Drug
Lead sponsor
Morphotek
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Baltimore, Maryland • Bethesda, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2014 · Synced Oct 29, 2026, 10:13 PM EDT
Active, not recruiting Phase 1 Interventional

TmPSMA-02 in mCRPC

NCT06046040
View directory record Official record
Conditions
Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Interventions
TmPSMA-02 CAR T Cells
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2042
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 29, 2026, 10:13 PM EDT
Withdrawn Phase 1 Interventional

CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA)

NCT03768310
View directory record Official record
Conditions
Non-hodgkin Lymphoma, Acute Lymphoblastic Leukemia
Interventions
CD19.CAR-multiVST for Group A, CD19.CAR-multiVST for Group B
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2040
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 29, 2026, 10:13 PM EDT
Terminated Phase 1 Interventional Results available

JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT02706405
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Interventions
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014, Cyclophosphamide, Durvalumab, Fludarabine
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Oct 29, 2026, 10:13 PM EDT
Recruiting Phase 1 Interventional

alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

NCT03692429
View directory record Official record
Conditions
Unresectable Metastatic Colorectal Cancer
Interventions
CYAD-101, FOLFOX, FOLFIRI
Drug
Lead sponsor
Celyad Oncology SA
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2036
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Oct 29, 2026, 10:13 PM EDT
Completed Phase 1 Interventional

Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis

NCT02245867
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 29, 2026, 10:13 PM EDT
Active, not recruiting Phase 1 Interventional

iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma

NCT01953900
View directory record Official record
Conditions
Osteosarcoma, Neuroblastoma
Interventions
GD2 T cells, VZV vaccine, Fludarabine, Cyclophosphamide
Genetic · Biological · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2034
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 29, 2026, 10:13 PM EDT
Recruiting Phase 1 Interventional

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

NCT07115745
View directory record Official record
Conditions
Refractory Autoimmune Diseases
Interventions
BMS-986515, Fludarabine, Cyclophosphamide, Tocilizumab
Genetic · Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 29, 2026, 10:13 PM EDT
Withdrawn Phase 1 Interventional

A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies

NCT04556266
View directory record Official record
Conditions
Leukemia, Lymphoma, Lymphoma, B-Cell
Interventions
CAR T-Cell Infusion
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 29, 2026, 10:13 PM EDT
Recruiting Phase 1 Interventional

FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT06609928
View directory record Official record
Conditions
Recurrent Childhood Acute Myeloid Leukemia, Refractory Childhood Acute Myeloid Leukemia
Interventions
FOLR1 CAR T-cells, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cyclophosphamide, Echocardiography Test, Fludarabine, Pheresis, Positron Emission Tomography
Biological · Procedure · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 6 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2042
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 29, 2026, 10:13 PM EDT
Active, not recruiting Phase 1 Interventional

19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers

NCT04464200
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Burkitt's Lymphoma, Primary CNS Lymphoma
Interventions
19(T2)28z1xx CAR T cells
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 29, 2026, 10:13 PM EDT
Terminated Phase 1 Interventional

A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer

NCT04227275
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
CART-PSMA-TGFβRDN, Cyclophosphamide, Fludarabine, Anakinra
Biological · Drug
Lead sponsor
Tceleron Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
9
States / cities
Tampa, Florida • Kansas City, Kansas • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 29, 2026, 10:13 PM EDT
Recruiting Phase 1Phase 2 Interventional

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

NCT05850234
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
AZD0120
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 29, 2026, 10:13 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

NCT06220201
View directory record Official record
Conditions
Multiple Sclerosis, Myasthenia Gravis
Interventions
CC-97540, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Birmingham, Alabama • Irvine, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 29, 2026, 10:13 PM EDT
Active, not recruiting Phase 1 Interventional

Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy

NCT05044039
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Acute Lymphocytic Leukemia
Interventions
Duvelisib, CAR T-cells
Drug · Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 29, 2026, 10:13 PM EDT
Recruiting No phase listed Observational

Outcomes After Chimeric Antigen Receptor Therapy and Radiation Therapy for Hematologic Malignancies

NCT04888338
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Data Capture, Electronic Medical Record
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 29, 2026, 10:13 PM EDT
Active, not recruiting Phase 2 Interventional

Descartes-08 for Patients With Systemic Lupus Erythematosus

NCT06038474
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Descartes-08
Drug
Lead sponsor
Cartesian Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Oceanside, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 29, 2026, 10:13 PM EDT
Recruiting Phase 1 Interventional

Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)

NCT04020575
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells, huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D
Biological
Lead sponsor
Minerva Biotechnologies Corporation
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2035
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 29, 2026, 10:13 PM EDT
Recruiting Phase 3 Interventional

A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

NCT07735637
View directory record Official record
Conditions
Newly Diagnosed Multiple Myeloma (NDMM)
Interventions
AZD0120, Cyclophosphamide, Fludarabine, Melphalan (part of ASCT), Lenalidomide
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2039
U.S. locations
46
States / cities
Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 29, 2026, 10:13 PM EDT
Terminated Phase 1 Interventional

Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma

NCT02209376
View directory record Official record
Conditions
Patients With Residual or Reccurent EGFRvIII+ Glioma
Interventions
CART-EGFRvIII T cells
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
San Francisco, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 29, 2026, 10:13 PM EDT